These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 17335769)

  • 1. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
    Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
    Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in research on peroxisome proliferator-activated receptor alpha-selective ligands.
    Miyachi H
    IDrugs; 2004 Aug; 7(8):746-54. PubMed ID: 15334308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
    Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
    Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver.
    Lapinskas PJ; Brown S; Leesnitzer LM; Blanchard S; Swanson C; Cattley RC; Corton JC
    Toxicology; 2005 Feb; 207(1):149-63. PubMed ID: 15590130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
    Fiévet C; Fruchart JC; Staels B
    Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
    Pinelli A; Godio C; Laghezza A; Mitro N; Fracchiolla G; Tortorella V; Lavecchia A; Novellino E; Fruchart JC; Staels B; Crestani M; Loiodice F
    J Med Chem; 2005 Aug; 48(17):5509-19. PubMed ID: 16107150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioassay-guided purification and identification of PPARalpha/gamma agonists from Chlorella sorokiniana.
    Chou YC; Prakash E; Huang CF; Lien TW; Chen X; Su IJ; Chao YS; Hsieh HP; Hsu JT
    Phytother Res; 2008 May; 22(5):605-13. PubMed ID: 18398904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
    Becker J; Delayre-Orthez C; Frossard N; Pons F
    Fundam Clin Pharmacol; 2006 Oct; 20(5):429-47. PubMed ID: 16968414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of an enzyme-linked immunosorbent assay to screen ligand of Peroxisome proliferator-activated receptor alpha.
    Cho MC; Lee S; Choi HS; Yang Y; Tae Hong J; Kim SJ; Yoon DY
    Immunopharmacol Immunotoxicol; 2009; 31(3):459-67. PubMed ID: 19263263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes.
    Mazzucotelli A; Viguerie N; Tiraby C; Annicotte JS; Mairal A; Klimcakova E; Lepin E; Delmar P; Dejean S; Tavernier G; Lefort C; Hidalgo J; Pineau T; Fajas L; Clément K; Langin D
    Diabetes; 2007 Oct; 56(10):2467-75. PubMed ID: 17646210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
    Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
    J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.
    Tanaka T; Masuzaki H; Ebihara K; Ogawa Y; Yasue S; Yukioka H; Chusho H; Miyanaga F; Miyazawa T; Fujimoto M; Kusakabe T; Kobayashi N; Hayashi T; Hosoda K; Nakao K
    Metabolism; 2005 Nov; 54(11):1490-8. PubMed ID: 16253638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPAR(alpha)- and PPAR(gamma)-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
    Ibabe A; Herrero A; Cajaraville MP
    Toxicol In Vitro; 2005 Sep; 19(6):725-35. PubMed ID: 15964169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
    J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel PPARalpha ligands by the structural modification of a PPARgamma ligand.
    Usui S; Fujieda H; Suzuki T; Yoshida N; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3249-54. PubMed ID: 16621530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.